Alector presents PhII data on lead dementia drug; Chinese oncology biotech nets modest Series A+
Back in June, GSK paid Alector $700 million to kickstart an alliance for rights to two drugs targeting a range of neurological diseases.
The next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
